Premed · Premed · Genetics
Lecture 24: Genetic Counseling and Testing
Genetics
Learning Objectives
By the end of this lecture, students will be able to:
- Define genetic counseling and describe its core principles (autonomy, non-directiveness, informed consent)
- Construct and interpret a three-generation pedigree using standard symbols
- Calculate recurrence risks for autosomal dominant, autosomal recessive, X-linked, and multifactorial conditions
- Describe the major types of genetic tests and their clinical applications
- Explain the concepts of sensitivity, specificity, positive predictive value, and variants of uncertain significance (VUS) in genetic testing
- Discuss the indications for prenatal, newborn, carrier, and predictive genetic testing
Lecture Content
I. Principles of Genetic Counseling
Genetic counseling is defined by the National Society of Genetic Counselors as the process of helping individuals and families understand and adapt to the medical, psychological, and familial implications of genetic contributions to disease. Several core principles guide this practice. Autonomy demands respect for the individual's right to make informed decisions. Non-directiveness requires the counselor to provide information and support without prescribing a course of action. Informed consent ensures that the patient understands the benefits, limitations, and risks of genetic testing before proceeding. Confidentiality protects genetic information from unauthorized disclosure. Beneficence and non-maleficence direct the counselor to benefit the patient while minimizing harm.
Referrals for genetic counseling are appropriate in many situations, including a personal or family history of a known or suspected genetic condition, advanced maternal age (35 years or older at delivery), abnormal prenatal screening results, consanguinity, recurrent pregnancy loss, ethnic background associated with increased carrier frequency for specific conditions, known carrier status, and the need for pre-test or post-test counseling. A typical genetic counseling session includes intake and pedigree construction (minimum three generations), risk assessment based on family history and inheritance pattern, discussion of genetic testing options with their benefits and limitations, psychosocial assessment and support, discussion of management, surveillance, and reproductive options, and follow-up with referral to support resources.
II. Pedigree Analysis and Risk Assessment
Standard pedigree symbols convey family structure and genetic status efficiently. Squares represent males and circles represent females, with diamonds used when sex is unspecified. Filled symbols indicate affected individuals, half-filled symbols indicate known carriers for autosomal recessive conditions, and a dot inside a circle indicates a carrier female for X-linked conditions. Horizontal lines connect partners, vertical lines descend to offspring, and double horizontal lines indicate consanguineous matings. A slash through a symbol indicates a deceased individual, and an arrow marks the proband (index case). Generations are labeled with Roman numerals and individuals within generations with Arabic numerals.
Recognizing inheritance patterns from pedigrees is a fundamental clinical skill. Autosomal dominant pedigrees show affected individuals in every generation, male-to-male transmission is possible, and offspring of affected individuals have a 50% recurrence risk. Autosomal recessive pedigrees often show affected individuals in a single generation (horizontal pattern), unaffected parents of affected children are carriers, consanguinity increases risk, and carrier-by-carrier matings carry a 25% recurrence risk. X-linked recessive pedigrees primarily affect males, show no male-to-male transmission, and carrier females are usually unaffected. X-linked dominant conditions affect both sexes but are often more severe in males, and affected fathers transmit the trait to all daughters but no sons. Mitochondrial pedigrees show maternal inheritance, with affected mothers transmitting to all children and no paternal transmission.
Bayesian analysis refines probability estimates using prior and conditional probabilities. For example, a woman whose brother has cystic fibrosis has a 2/3 prior probability of being a carrier (given that she is unaffected). If she has had unaffected children, each child slightly reduces her posterior probability of being a carrier, because carriers have a 3/4 chance per pregnancy of an unaffected child while non-carriers have a probability of 1.
<image>Panel A: Standard pedigree symbols reference chart — showing the symbols for male, female, affected, unaffected, carrier, deceased, proband, consanguineous mating, twins (monozygotic and dizygotic), pregnancy, and miscarriage/termination, with labels for each. Panel B: Five example pedigrees illustrating the five major inheritance patterns — autosomal dominant, autosomal recessive, X-linked recessive, X-linked dominant, and mitochondrial — each with three generations, key features annotated (e.g., "no male-to-male transmission" for X-linked, "every generation affected" for autosomal dominant). Panel C: Bayesian analysis worked example — a table showing prior probability, conditional probability, joint probability, and posterior probability for a woman who may be a carrier for an autosomal recessive condition, incorporating information from unaffected children to update the risk estimate.</image>
III. Types of Genetic Tests
Cytogenetic tests include karyotyping, which visualizes chromosome number and structure to detect aneuploidy, large deletions, and translocations; FISH, which uses fluorescent probes for targeted detection of specific chromosomal regions; and chromosomal microarray (CMA), which detects copy number variants at higher resolution than karyotype.
Molecular genetic tests range from narrow to broad in scope. Single-gene testing uses Sanger sequencing of a specific gene when clinical suspicion is high. Gene panels employ NGS to sequence multiple genes simultaneously. Whole exome sequencing (WES) covers all protein-coding regions, and whole genome sequencing (WGS) covers the entire genome including non-coding regions. Targeted variant analysis tests for specific known pathogenic variants, such as BRCA1 founder mutations in Ashkenazi Jewish populations.
Biochemical genetic tests include enzyme activity assays (such as alpha-galactosidase A for Fabry disease), metabolite analysis (such as phenylalanine levels for PKU), and protein-based assays (such as hemoglobin electrophoresis for sickle cell disease). Pharmacogenomic tests assess genetic variants affecting drug metabolism and are covered in detail in Lecture 25.
IV. Interpreting Genetic Test Results
The ACMG/AMP five-tier variant classification system categorizes variants as pathogenic (clearly disease-causing), likely pathogenic (strong but not definitive evidence), variant of uncertain significance (VUS) (insufficient evidence to classify), likely benign (strong evidence against pathogenicity), or benign (clearly not disease-causing). VUS findings are extremely common, especially in multi-gene panels and WES/WGS. They cannot be used for clinical decision-making, may be reclassified over time as evidence accumulates, and often cause significant patient anxiety.
Test performance metrics are essential for interpreting results. Sensitivity (clinical sensitivity) is the proportion of affected individuals who test positive. Specificity is the proportion of unaffected individuals who test negative. Positive predictive value (PPV) is the probability that a positive result is a true positive and depends on disease prevalence. Negative predictive value (NPV) is the probability that a negative result is a true negative. Beyond these, analytical validity measures the accuracy of the test in detecting the variant, clinical validity measures how well the test predicts the clinical condition, and clinical utility asks whether the test result changes management or improves outcomes.
<image>Panel A: Hierarchy of genetic testing approaches — a pyramid or stepwise diagram showing targeted variant analysis (narrowest, most specific) at the top, then single-gene testing, then gene panels, then whole exome sequencing, then whole genome sequencing (broadest, most comprehensive) at the base; each level shows typical indications, number of genes tested, turnaround time, cost, and likelihood of VUS findings. Panel B: ACMG variant classification schema — a horizontal spectrum from Benign to Pathogenic with the five categories shown as colored blocks; key criteria for each classification are listed below (population frequency, functional studies, segregation data, computational predictions, de novo status). Panel C: 2x2 contingency table illustrating sensitivity, specificity, PPV, and NPV — with disease status (affected/unaffected) on one axis and test result (positive/negative) on the other; true positives, false positives, true negatives, and false negatives are labeled with formulas for each metric.</image>
V. Clinical Applications of Genetic Testing
Prenatal testing includes both screening and diagnostic approaches. Screening tests are non-invasive and assess risk: the first-trimester combined screen uses nuchal translucency ultrasound plus maternal serum markers (free beta-hCG and PAPP-A), while non-invasive prenatal testing (NIPT) analyzes cell-free fetal DNA in maternal blood with high sensitivity for trisomies 21, 18, and 13 and sex chromosome aneuploidies. NIPT is a screening test, not a diagnostic one. Diagnostic tests are invasive but definitive: chorionic villus sampling (CVS) at 10-13 weeks samples placental tissue, and amniocentesis at 15-20 weeks samples amniotic fluid. Both carry a small risk of miscarriage (approximately 0.1-0.3%) and enable karyotyping, CMA, or targeted molecular testing on fetal cells.
Newborn screening (NBS) is a mandated public health program that screens for 30-50 or more conditions, varying by jurisdiction. A blood spot from a heel prick is collected at 24-48 hours of life. Tests include tandem mass spectrometry for metabolic disorders, hemoglobin electrophoresis for sickle cell disease, immunoreactive trypsinogen for cystic fibrosis, and TSH for hypothyroidism. Screening criteria require that the condition be treatable, the test reliable, and early detection must improve outcomes.
Carrier screening is offered based on ethnicity (CF in European descent, Tay-Sachs in Ashkenazi Jewish, sickle cell in African descent populations) or through expanded carrier screening panels (pan-ethnic, covering 100 or more conditions). It is ideally performed preconception so that couples can be informed of reproductive options; when both partners carry the same autosomal recessive condition, each pregnancy carries a 25% risk.
Predictive/presymptomatic testing identifies individuals at risk for a genetic condition that has not yet manifested. Testing for Huntington disease, an adult-onset autosomal dominant condition with no cure, requires extensive pre-test counseling, psychological assessment, and informed consent. Such testing can provide relief from uncertainty but may also cause psychological distress. GINA (the Genetic Information Nondiscrimination Act of 2008 in the US) prohibits genetic discrimination by health insurers and employers but does not cover life, disability, or long-term care insurance.
VI. Reproductive Options for At-Risk Couples
Couples at risk for having a child with a genetic condition have several reproductive options. They may pursue natural conception with prenatal diagnosis through CVS or amniocentesis, followed by an informed decision about pregnancy continuation. Preimplantation genetic testing (PGT) through IVF allows genetic testing of embryos before transfer: PGT-M tests for monogenic disorders, PGT-A tests for aneuploidy, and PGT-SR tests for structural rearrangements. Other options include gamete donation using donor sperm or oocytes from a non-carrier, adoption, or accepting the risk and conceiving naturally with full awareness. The genetic counselor's role is to present all options without bias and support the couple's informed decision.
